Apixaban as a Direct Factor Xa Inhibitor: A Comprehensive Review of Pharmacokinetics, Clinical Efficacy, and Safety

Apixaban is a selective, reversible oral factor Xa inhibitor used to prevent and treat thromboembolic disorders. This review summarises its pharmacology, pharmacokinetics, mechanism, clinical uses, and safety. By inhibiting factor Xa, Apixaban reduces thrombin generation and clot formation. It has about 50% oral bioavailability, a 12-hour half-life, and multiple elimination routes; renal excretion accounts for roughly 27% of clearance. Uses include stroke prevention in non-valvular atrial fibrillation, treatment of deep vein thrombosis and pulmonary embolism, prevention of recurrent venous thromboembolism, and thromboprophylaxis after hip or knee replacement. Clinical trials support its efficacy and favourable benefit-risk profile versus conventional anticoagulants in appropriately selected patients. Bleeding is the main adverse effect; interactions, organ impairment, and specific patient groups require consideration. Although routine international normalized ratio monitoring is unnecessary, regular clinical assessment and appropriate laboratory tests help ensure safety. Apixaban offers convenient, effective anticoagulation, but individualised prescribing and ongoing monitoring are essential to optimize outcomes and limit complications.